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Abstract
Transmitted drug resistance (TDR) is a clinical and epidemiological problem because it may contribute to failure of
antiretroviral treatment. The prevalence of TDR varies geographically, and its prevalence in Sweden during the last decade
has not been reported. Plasma samples from 1,463 patients newly diagnosed with HIV-1 infection between 2003 and 2010,
representing 44% of all patients diagnosed in Sweden during this period, were analyzed using the WHO 2009 list of
mutations for surveillance of TDR. Maximum likelihood phylogenetic analyses were used to determine genetic subtype and
to investigate the relatedness of the sequences. Eighty-two patients showed evidence of TDR, representing a prevalence of
5.6% (95% CI: 4.5%–6.9%) without any significant time trends or differences between patients infected in Sweden or abroad.
Multivariable logistic regression showed that TDR was positively associated with men who have sex with men (MSM) and
subtype B infection and negatively associated with CD4 cell counts. Among patients with TDR, 54 (68%) had single
resistance mutations, whereas five patients had multi-drug resistant HIV-1. Phylogenetic analyses identified nine
significantly supported clusters involving 29 of the patients with TDR, including 23 of 42 (55%) of the patients with TDR
acquired in Sweden. One cluster contained 18 viruses with a M41L resistance mutation, which had spread among MSM in
Stockholm over a period of at least 16 years (1994–2010). Another cluster, which contained the five multidrug resistant
viruses, also involved MSM from Stockholm. The prevalence of TDR in Sweden 2003–2010 was lower than in many other
European countries. TDR was concentrated among MSM, where clustering of TDR strains was observed, which highlights
the need for continued and improved measures for targeted interventions.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) is characterized
by a rapid rate of evolution and is therefore prone to accumulate
mutations that confer resistance to antiretroviral drugs during
suboptimal antiretroviral therapy (ART). Viruses with resistance
mutations may be transmitted and such transmitted drug
resistance (TDR) is an important clinical and epidemiological
problem, because it can contribute to failure of first-line ART [1].
For this reason the World Health Organization (WHO) recom-
mends that countries that have installed ART programs should
establish sentinel surveillance systems of TDR and provide
evidence-based recommendations for prevention of HIV drug
resistance [2,3]. Furthermore, Swedish and international treat-
ment guidelines recommend that resistance testing should be
performed in newly diagnosed patients [4–6]. The reported
prevalence of TDR in more recent, large studies from different
European countries and the United States (US) range from 6.1%
in Denmark to 14.6% in the U.S. [7–12]. Furthermore, the pan-
European SPREAD study reported a TDR prevalence of 8.4% in
Europe in 2002–2005 [13,14].
Sweden, with a population of approximately 10 million
inhabitants, has a low prevalence and incidence of HIV-1. At
the end of 2010 there had been a cumulative number of 9,400
diagnosed cases and approximately 5,300 persons were estimated
to be living with HIV-1 in the country (www.smi.se). Among 3,257
patients with known transmission route diagnosed in 2000–2009,
61% were heterosexually infected, 29% were men who have sex
with men (MSM) and 10% were intravenous drug users (IDUs).
The proportion of patients infected abroad was 86%, 44% and
25% in these three transmission groups, respectively. Immigrants
from high-prevalence countries constituted 60% of the patients
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ART has been universally available in Sweden since zidovudine
was introduced in 1986 and is prescribed by specialists in
infectious diseases or equivalent according to national HIV
treatment guidelines [4] (updated version available in Swedish at
www.rav.nu). Despite the long use of ART in Sweden there is
incomplete knowledge about TDR and there have only been three
previous studies which were relatively small and investigated
patients diagnosed before 2003 [15–17]. The present study was
designed to prospectively and longitudinally monitor TDR in
Sweden using representative sampling. We report results for 1463
patients diagnosed between 2003 and 2010, which represents 44%
of all patients diagnosed in Sweden during this period. The
prevalence of TDR was relatively low, 5.6%.
Materials and Methods
Patients
Patients were recruited from January 2003 until June 2010. The
five clinical centers for HIV care in the three largest Swedish cities
(Stockholm, Gothenburg and Malmo ¨) took part in the study from
the start. Fifteen additional HIV centers were added from 2005 so
that 20 of the 29 centers in Sweden eventually took part in the
study. The study was coordinated with the EU project SPREAD
(Strategy to Control SPREAD of HIV drug resistance) (www.esar-
society.eu), which is a multinational, multicentre surveillance
program aimed at determining the prevalence of TDR in Europe.
The study protocols and data collection forms of SPREAD were
used with a few modifications. Patient data included age, gender,
country of origin, suspected country of acquisition of infection,
clinical staging, transmission route, last negative and first positive
HIV test, laboratory evidence of primary HIV-1 infection.
Laboratory documented primary HIV-1 infection was defined as
an acute seroconversion syndrome confirmed by: a) HIV-1
antibody seroconversion, or b) HIV-1 antibody negativity+positive
HIV-1 RNA PCR, or c) HIV-1 antibody negativity+positive HIV-
1 DNA PCR, or d) HIV-1 antibody negativity+positive HIV-1
antigen test; in all cases later re-confirmed by a full HIV-1
antibody seroconversion. Patients originating from high-preva-
lence countries (defined as countries with a national HIV
prevalence above 1% according to the 2002 UNAIDS estimates)
were considered to have acquired HIV-1 infection heterosexually
unless specifically reported as being MSM or IDUs. The inclusion
criteria were: 1) HIV-1 infection newly diagnosed in Sweden
during the study period; 2) Sample for resistance testing obtained
within 180 days following diagnosis; 3) No known exposure to
ART;. Exclusion criteria were: 1) HIV-2 infection. 2) HIV-1
infection previously diagnosed outside of Sweden.
Informed written or oral consent was obtained from all adult
participants and from the next of kin, caregivers or guardians on
the behalf of the minors/children participants. The research was
conducted according to the Declaration of Helsinki and was
approved by the Regional Medical Ethics Board in Stockholm,
Sweden (Dnr 02-367, 04-797 and 2007/1533) that had permitted
the use of oral consent, which was documented in the patient
records, to minimize the risk of selection biases due to patient
drop-out because some ethnic groups of participants were known
to be willing to take part in the study, but reluctant to provide
written consent.
Measurements of plasma HIV-1 RNA levels and CD4
counts
Plasma HIV-1 RNA levels were measured using the Cobas
AmpliPrep sample preparation system followed by analysis using
the Cobas Amplicor HIV-1 monitor version 1.5 or the Cobas
TaqMan HIV-1 v1.0 or v2.0 (Roche Molecular Systems, Basel,
Switzerland). CD4+ T-lymphocyte (CD4) cells were enumerated
using flow cytometry.
Genotypic HIV-1 resistance testing
Genotypic HIV-1 resistance testing for 1368 of the samples was
performed at the Swedish Institute for Infectious Disease Control
using a published in-house method that targets amino acids 1–99
in the protease and 1–253 in the reverse transcriptase [18]. The
test has undergone regular quality control within ENVA
genotyping proficiency programme [19]. Resistance testing was
performed on plasma samples that had been stored at 270uC until
testing. If testing of plasma was unsuccessful, we attempted
analysis on HIV-1 DNA from peripheral blood mononuclear cells
(PBMCs) if available. For 12 patients we used sequences obtained
from PBMCs, 7 of these patients had plasma HIV-1 RNA levels
lower than 1000 copies/mL. For 83 patients we obtained
sequences from routine resistance testing performed at the
Karolinska University Hospital (n=12) or the Sahlgrenska
University Hospital (n=71). To qualify for the subsequent
analyses the sequences had to include amino acids 15–90 in the
protease and amino acids 41–219 in the reverse transcriptase, but
a majority of the sequences covered the entire amplicon length of
the in-house resistance test.
The sequences were assembled and edited using the Sequench-
er
TM software (Gene Codes Corporation, Ann Arbor, MI, US).
TDR was identified using the WHO 2009 list of mutations for
surveillance of TDR [20] as implemented in the Calibrated
Population Resistance tool (v5.0 beta) [21] available at the
Stanford HIV Drug Resistance Database (hivdb.stanford.edu).
The following resistance mutations were scored: to nucleoside
reverse transcriptase inhibitors (NRTIs): M41L, K65R, D67N/G/
E, T69D/insertion, K70R/E, L74V/I, V75M/T/A/S, F77L,
Y115F, F116Y, Q151M, M184V/I, L210W, T215Y/F/I/S/C/
D/V/E, K219Q/EN/R; to non-nucleoside reverse transcriptase
inhibitors (NNRTIs): L100I, K101E/P, K103N/S, V106A/M,
V179F, Y181C/I/V, Y188C/L/H, G190A/S/E, P225H,
M230L; and to protease inhibitors (PIs): L23I, L24I, D30N,
V32I, M46I/L, G48V/M, I50L/V, F53L/Y, I54V/L/M/A/T/
S, G73S/T/C/A, L76V, V82A/T/F/S/C/M/L, N83D, I84V/
A/C, N88D/S, L90M. The susceptibility of the viruses to
antiretroviral drugs was predicted using the Stanford HIVdb,
ANRS and Rega algorithms as implemented in the HIValg tool
also available at the Stanford HIV Drug Resistance Database.
Subtype determinations and phylogenetic tree analyses
To determine the HIV-1 genetic subtype of the viruses, the pol
sequences were manually aligned with the subtype reference
sequence dataset from the Los Alamos HIV Sequence Database
(www.hiv.lanl.gov) using BioEdit [22]. Because resistance muta-
tions might lead to homoplasy (convergent evolution) all 23 codons
with resistance mutations in the dataset were removed. Subtype
determination was done by maximum likelihood (ML) phyloge-
netic trees using PhyML [23] with the GTR+I+G substitution
model, which was the best fitted model according to Findmodel
(www.hiv.lanl.gov). Problematic sequences were further investi-
gated using the Rega HIV-1 Subtyping Tool (version 2.0) (http://
regaweb.med.kuleuven.be), HIV BLAST analyses (hiv.lanl.gov),
and Simplot analyses (http://sray.med.som.jhmi.edu/SCRoftware/
simplot). ML phylogenetic trees were also used to study detailed
evolutionary relationships within subtype B. In these analyses we
included previously published sequences from 194 MSM who were
newly diagnosed with HIV-1 infection in Stockholm, Sweden in
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sequences that were significantlyseparated from the restof the tree by
an approximate likelihood ration test (aLRT) value.0.95 in PhyML
[24], but bootstrap analyses were also performed using neighbor-
joining phylogenetic trees that were constructed with the maximum
composite likelihood substitution model in Mega v4.1 [25]. For
similar scientific and ethical reasons as explained in [26,27], only a
proportion (approximately 15%) of the anonymized sequences is
accessible via GenBank (accession numbers, JQ698667–JQ698874).
In brief, the sequences analyzed in the present study constitute a
dataset that is very representative of an entire country and thereby, in
principle,allowforthereconstructionofentiretransmissionnetworks.
Inappropriate use of the data could thereby endanger the privacy of
the patients, which is especially problematic because HIV-1
sequences frequently have been used in court cases. Furthermore
and from a scientific point of view, the consequences of open and
uncontrolled access to such densely sampled sequences could
jeopardize the future publication (and, thus, the investigation) of
similarly complete datasets and could thereby be counterproductive
even from an ‘‘open-access’’ perspective [27]. However, the entire
datasetcan be used for well-defined projectsthat havepassed Swedish
ethical clearance and are in accordance with the guidelines of the
Swedish cohort, if a corresponding project proposal is approved by
the scientific board.
Statistical analyses
The 95% confidence interval (95% CI) of the prevalence of
TDR was calculated using the binomial distribution and the exact
method. The Chi-square and Mann-Whitney U tests were used as
appropriate. Univariable and multivariable logistic regression
analyses were used to estimate odds ratios with 95% CI for the
association between TDR status and different factors. Statistical
analyses were carried out using Statistica v10 and Stata v 8.2.
Results
General characteristics of the study subjects
A total of 1491 patients met the inclusion criteria. Most of study
subjects (n=1009) were recruited from Stockholm; of the
remaining patients 147 were from Gothenburg, 122 from Malmo ¨
and 213 from the rest of the country. Six eligible patients were
excluded prior to data analysis because the sequence did not
include all relevant resistance positions and 22 patients were
excluded because resistance testing was unsuccessful. The latter
patients had a median plasma HIV-1 RNA level of 500 copies/mL
and 14 patients had ,1000 copies/mL. Thus, the analyses
included 1463 patients, of whom 291 (20%) were defined as
having a recent infection based on a laboratory documented
primary HIV-1 infection or a negative HIV-1 serology ,1 year
prior to diagnosis. The remaining patients had HIV-1 infections of
unknown duration. The median time between diagnosis and
sampling for resistance testing was 11 days (range 0–180 days).
The general characteristics of the study subjects are shown in
Table 1. Approximately 70% of the study subjects were men and
30% were females. The median age of all study subjects was 38
years and men were significantly older than women (median age
40 years vs. 33 years; p,0.001, Mann-Whitney U-test). The most
frequently reported transmission routes were: heterosexual (51%,
with 31% originating from high-prevalence countries), MSM
(37%) and IDU (9%). A high proportion of the patients (832 of
1463; 57%) were reported to have been infected abroad. The most
frequently reported countries of infection were: Sweden (42%),
Thailand (12.3%), Ethiopia (3.3%), Eritrea (2.7%), Kenya (2.4%),
Spain (1.9%), and Somalia (1.7%). The distribution of countries of
origin was quite similar to the countries of infection (data not
shown).
The characteristics of the study subjects were compared to
national HIV surveillance data (www.smi.se) (Table S1). Overall,
we sampled around 44% of all patients diagnosed in Sweden in
2003–2009 and in addition 136 patients who were diagnosed in
the first half of 2010. The distribution of the study population was
reasonably well matched with that of all diagnosed patients.
However, MSM were somewhat over-represented in the study
population (36% vs. 24%), but it should be noted that data on the
route of transmission were not available for 16% of the patients in
the national data. In agreement with this, we observed an over-
representation of men and individuals infected in Sweden in the
study population.
Genetic HIV-1 subtypes
The genetic subtype of the sequenced pol gene fragment was
subtype B for 41% of the patients, circulating recombinant form
01_AE (CRF01_AE) 19%, subtype C 15%, subtype A 9%,
CRF02_AG 8% and subtype D 2%. Remaining patients (6%)
had virus that was classified as other subtypes (F and G), circulating
recombinant forms (CRFs) (CRF03_AB, CRF06_cpx, CRF07_BC,
CRF09_cpx, CRF10_CD, CRF11_cpx, CRF12_BF, CRF13_cpx,
CRF20_BG, CRF24_BG, CRF33_01B, CRF34_01B, CRF35_
AD, CRF49_cpx), unique recombinant forms or unclassifiable (data
not shown). The large proportion of CRF01_AE infections was
linked to travel to and immigration from Thailand where
CRF01_AE is common, but also to an outbreak of CRF01_AE
infections among IDUs in Stockholm in 2007 [28]. In line with this,
the proportion of subtype B infections decreased significantly over
time among patients infected in Sweden (p,0.001), while the
proportion of CRF01_AE infections increased significantly
(p=0.015).
TDR over-represented in MSM and subtype B
Eighty-two of the 1463 study subjects had viruses with
mutations indicative of TDR according to the WHO 2009 list of
mutations for surveillance of transmitted drug resistance [20]
(Table 1). Thus, the prevalence of TDR was 5.6% (95% CI:
4.5%–6.9%) in this study population. The prevalence of TDR was
significantly higher among men than in women (OR 2.38; 95% CI
1.30–4.34) (Table 1), which can be explained by the higher
prevalence of TDR among MSM (9.5%) than in the other three
main transmission groups.
The prevalence of TDR was slightly, but non-significantly,
higher among patients infected in Sweden or abroad (42 of 631
[6.7%] vs. 40 of 832 [4.8%], p=0.13; Chi square test). However,
when patients infected abroad were broken down into subgroups,
the prevalence of TDR was significantly lower in patients infected
in Sub-Saharan Africa (3.3%, p=0.019) and non-significantly
higher among patients infected in the rest of Europe (9.4%,
p=0.28) as compared to patients infected in Sweden. There were
no significant differences in prevalence of TDR among MSM
infected in Sweden or abroad (8.8% vs 10.9%; p=0.44, Chi
square test) or among patients who were heterosexually infected in
Sweden vs. other low prevalence countries (4.8% vs. 3.7%;
p=0.66 Chi square test). The study was not powered to carry out
such comparison for the remaining transmission groups. The
prevalence of TDR did not differ between patients attending care
in Stockholm, Gothenburg, Malmo ¨ or other study sites. TDR was
more common among patients infected with subtype B (9.1%)
than among patients infected with other subtypes (3.1%)
(p=0.0025, Chi square test), whereas differences between other
subtypes were non-significant (data not shown). Patients with
Low HIV-1 Transmitted Drug Resistance in Sweden
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33484recent infections (,1 year) and patients with unknown duration of
infection had similar prevalence of TDR (15 of 291 [5.2%] vs. 67
of 1172 [5.7%]; p=0.71, Chi square test). Among the 15 patients
with recent infections and TDR, 10 were MSM infected in
Sweden indicating that viruses with TDR mutations were being
transmitted among MSM in Sweden during the study period.
Patients with and without TDR had similar median CD4 cell
counts and plasma HIV-1 RNA levels.
Table 1. Characteristics of patients with and without transmitted drug resistance (TDR).
Characteristics Total Patients with TDR (%) Patients without TDR (%) OR univariable (95% CI) P-value
Patients 1463 82 (5.6%) 1381 (94.4%)
Sex [n]
Female 440 13 (3.0%) 427 (97.0%) 1
Male 1023 69 (6.7%) 954 (93.3%) 2.38 (1.3–4.3) 0.005
Age [median (range)] 38 39 (1–83) 37 (13–64) 0.27
Year of diagnosis [n] 1.05 (0.95–1.2) 0.34
2003 126 7 (5.6%) 119 (94.4%)
2004 153 8 (5.2%) 145 (94.8%)
2005 155 11 (7.1%) 144 (92.9%)
2006 192 4 (2.1%) 188 (97.9%)
2007 239 10 (4.2%) 229 (95.8%)
2008 221 16 (7.2%) 205 (92.8%)
2009 241 18 (7.5%) 223 (92.5%)
2010 136 8 (5.9%) 128 (94.1%)
Route of transmission [n]
Homosexual/bisexual 536 51 (9.5%) 485 (90.5%) 1
Intravenous drug use 136 4 (2.9%) 132 (97.1%) 0.29 (0.10–0.81) 0.019
Heterosexual 752 25 (3.3%) 727 (96.7%)
High-prevalence country 453 13 (2.9%) 440 (97.1%) 0.28 (0.15–0.52) .0.001
Low-prevalence country 299 12 (4.2%) 287 (96.0%) 0.40 (0.21–0.76) 0.005
Mother-to-child 9 1 (11.1%) 8 (88.9%)
Other/Unknown 30 1 (3.3%) 29 (96.7%)
Region of infection [n]
Sweden 631 42 (6.7%) 589 (93.3%) 1
Europe, except Sweden 128 12 (9.4%) 116 (90.6%) 1.45 (0.74–2.8) 0.28
Sub-Saharan Africa 336 10 (3.0%) 326 (97.0%) 0.43 (0.21–0.87) 0.019
Asia 216 9 (4.2%) 207 (95.8%) 0.61 (0.29–1.3) 0.19
Americas 51 3 (5.9%) 48 (94.1%) 0.88 (0.26–2.9) 0.83
Other/Missing data 101 6 (5.9%) 95 (94.1%)
HIV-1 subtype [n]
Subtype B 605 55 (9.1%) 550 (90.9%) 1
Subtype A 130 2 (1.5%) 128 (98.5%) 0.15 (0.04–0.65) 0.011
Subtype C 224 5 (2.2%) 219 (97.8%) 0.23 (0.09–0.57) 0.002
CRF01_AE 273 10 (3.7%) 263 (96.3%) 0.38 (0.19–0.76) 0.006
CRF02_AG 114 2 (1.8%) 112 (98.2%) 0.18 (0.04–0.76) 0.020
Subtype D 25 0 (0.0%) 25 (100%)
Other 92 8 (8.7%) 84 (91.3%)
Duration of infection [n]
Undefined 1172 67 (5.7%) 1105 (94.3%) 1
,1 year 291 15 (5.2%) 276 (94.8%) 0.89 (0.50–1.6) 0.70
CD4+ T-cell counts (cells/ml)
median (range) 320 279 (0–1480) 325 (0–2030) 0.34
Plasma HIV-1 RNA levels [log copies/ml
median (range)] 4.8 4.8 (2.3–6.8) 4.8 (,1.6–7.6) 0.99
doi:10.1371/journal.pone.0033484.t001
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iable logistic regression models were explored. The final model is
shown in Table 2, which showed that TDR was positively
associated with the MSM transmission route, subtype B infection
and negatively associated with log transformed CD4 cell counts.
Trend towards increasing TDR among patients infected
in high-prevalence countries
The prevalence of TDR showed relatively high variation over
the study period; from 2.1% in 2006 to 7.5% in 2009 (Table 1),
but there was no clear trend over time even if infection route was
included as a confounder to adjust for the higher prevalence of
TDR among MSM (p=0.32, logistic regression). When time
trends were investigated for individual transmission groups, we
observed a non-significant trend towards an increasing prevalence
of TDR among patients from high-prevalence countries
(p=0.071; logistic regression), but this should be interpreted with
caution because there were only 13 such patients with TDR. In
the three remaining major transmission groups, i.e. IDUs, MSM,
heterosexual transmission in low-endemic countries, there were no
significant changes in TDR over time.
A majority of patients with TDR had singleton resistance
mutations
A majority of the patients with TDR (56 of 82; 68%) had virus
with single drug resistance mutations (Table 3). Of these singleton
mutations, 35 were NRTI-related, 16 were NNRTI-related and 5
were PI-related. The M41L mutation represented almost half (16
of 34) of the NRTI-related singleton mutations and the K103N
mutation represented two-thirds (10 of 15) of the NNRTI-related
singleton mutations. As shown in Table 3, 80% (28 of 35) of the
patients with single mutations associated with NRTI resistance
were predicted to be fully susceptible to all NRTIs according to the
Rega algorithm. Similarly, all five patients with single PI-related
mutations were predicted to be fully susceptible to all PIs. In
contrast, 14 of 16 patients with NNRTI-related singleton
mutations were predicted to have high-level resistance to efavirenz
and nevirapine, but resistance to etravirin was uncommon. Drug
susceptibility prediction using the Stanford or ANRS algorithms
gave similar, but not identical, results (data not shown).
Twenty-six patients had viruses with more than one TDR
mutation (Table 4). A majority of these patients were MSM who
had been infected in Sweden. Multidrug resistance (MDR)
involving all three drug as well as the Q151M complex [29] was
observed in five patients (patients 57–61). Dual class resistance was
observed in five patients, whereas the remaining 17 patients had
Table 2. Multivariable model showing factors that were
significantly associated with TDR.
Variable Odds ratio 95% CI P-value
MSM 2.15 1.14–4.07 0.018
Subtype B 1.96 1.03–3.73 0.041
Ln CD4 counts 0.81 0.69–0.96 0.013
doi:10.1371/journal.pone.0033484.t002
Table 3. Susceptibility of HIV-1 strains with single transmitted drug resistance mutations.
Patient id n Mutation
1 Predicted susceptibility to
NRTI related AZT D4T FTC 3TC ABC DDI TDF
1–16
2 16 M41L S S S S S S S
17 1 D67N S S S S S S S
1 8 1 K 7 0 E S S III I I
19–23 5 F77L S S S S S S S
24 1 M184V S S R R S S S
25–29
3 5 T215C/S I I S S S S S
30–35 6 K219N/Q/R S S S S S S S
NNRTI related EFV NVP ETR
36–37 2 K101E S S S
38–47
4 10 K103N R R S
48–49
5 3 Y181C R R I
51 1 G190AG R R S
PI related ATV/r DRV/r FPV/r IDV/r LPV/r SQV/r TPV/r
52–54 3 M46L S S S S S S S
55 1 I54IL S S S S S S S
56 1 I85V S S S S S S S
Susceptibility was predicted using the Rega resistance interpretation algorithm (V6.4.1) (ref). NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside
reverse transcriptase inhibitor; PI, protease inhibitor;
1)In eight patients the single resistance mutation was present as a polymorphism together with wild-type virus;
2)Ten patients in cluster no 4, two patients in cluster no. 5, one patient in cluster no. 2;
3)Two patients (with T215S) in cluster no. 6;
4)Two patients in cluster no. 7 and two patients in cluster no. 8;
5)Two patients in cluster no. 9.
doi:10.1371/journal.pone.0033484.t003
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33484two or more TDR mutations belonging to a single drug class. A
majority of the latter patients had thymidine analogue mutations
(TAMs) [29].
Phylogenetic clustering of TDR viruses
ML phylogenetic trees were constructed for each HIV-1
subtype to investigate the relationships of viruses with TDR
mutations relative to a background of viruses without such
mutations. We identified nine clusters that contained two or more
TDR viruses and were significantly supported with aLRT
values.0.95. The characteristics of the patients involved these
nine clusters are given in Tables 3 and 4. Seven of the clusters
were of subtype B, one cluster was classified as CRF01_AE and
finally one cluster consisted of two viruses of unclassifiable subtype.
Among 42 patients with TDR who were infected in Sweden, 23
(55%) were involved in clusters. In contrast, only 5 of 33 (27%)
patients infected abroad were involved in clusters (p=0.004,
Fisher exact test). Figure 1 shows a ML tree for subtype B
sequences, in which the seven subtype B TDR clusters are
highlighted. In this analysis we also included 194 subtype B
sequences from MSM diagnosed as HIV infected in Stockholm in
1992–2002 [17]. Four of the seven subtype B clusters included
sequences from the 1992–2002 dataset. The largest TDR cluster
(cluster 4) consisted of 18 MSM from Stockholm with viruses that
had the M41L resistance mutation (Figure 1). Two of the M41L
viruses had additional mutations (T215N and M46LM, respec-
tively). Eleven of the 18 patients in the M41L cluster were part of
the present study and seven belonged to the 1992–2002 dataset.
The first patient in the M41L cluster was diagnosed in 1994 [17].
Among the 11 patients diagnosed in 2003–2010, we found that
seven patients had recent infections as evidenced by a documented
primary HIV-1 infection (n=2) or a negative HIV-1 antibody
assay ,1 year prior to diagnosis (n=5). This includes two patients
diagnosed in 2010, which shows that the M41L variant has been
circulating in Stockholm between 1994 and 2010. Cluster no. 1
was the second largest cluster and consisted of all five MDR
viruses, which were observed in MSM diagnosed between 2003
and 2010 (Figure 1). Remaining subtype B TDR clusters were
small and contained two to four sequences.
Discussion
In this first comprehensive study of TDR in Sweden we have
prospectively investigated a representative sample of 1463 persons
who were newly diagnosed with HIV-1 infection between 2003
and 2010. We found that the prevalence of TDR was relatively
low, 5.6% (95% CI: 4.5%–6.9%) and stable over time. TDR was
positively associated with the MSM transmission route, subtype B
infection and negatively associated with CD4 cell counts.
The prevalence of TDR in Sweden was low compared to many
other European countries, the U.S. as well as the pan-European
SPREAD study [7–14]. The comparably low prevalence of TDR
in Sweden in part can be explained by the fact that 32% of the
study subjects were immigrants from high-prevalence countries,
where access to ART sometimes has been limited. However, it
should be pointed out that 12.3% of the infections occurred in
Thailand, which is a high-prevalence country, but where ART has
been available for a number of years and where a recent report
indicated a TDR prevalence of 14% [30]. The large proportion of
patients originating from and infections occurring in Thailand
probably reflects the fact that Thailand is a popular travel
destination for Swedish tourists and that there is significant
immigration from Thailand. Another reason for the low
prevalence of TDR might be that a high proportion of patients
on ART in Sweden have fully suppressed virus replication with
plasma HIV-1 RNA levels ,50 copies per mL as shown in the
Swedish national register InfCareHIV (national average 92% in
2010, http://infcare.se/hiv). The risk of sexual HIV-1 transmis-
sion from patients with ‘‘undetectable’’ virus levels is very low [31–
33], which means that most transmissions occur from subjects
without ongoing treatment.
The prevalence of TDR varied from 2.1% in 2006 to 7.5% in
2009, but there was no significant trend over time in the entire
study population or in individual transmission routes. However,
there was a non-significant increase in TDR among patients from
high-endemic countries (p=0.071). Although this non-significant
trend should be interpreted with caution, it is in line with recent
reports showing an increasing prevalence of TDR among sub-
Saharan Africans residing in Spain [34] as well as indications of
increasing levels of TDR in sub-Saharan Africa and Asia,
including Thailand [30,35].
Phylogenetic tree analyses were used to investigate clustering of
sequences from the study subjects with TDR. We found that more
than half (55%) of the TDR patients infected in Sweden were
involved in clusters, in contrast to 27% of those reported to have
been infected abroad. One cluster was large and contained 18
viruses with the M41L resistance mutation. This M41L cluster
represents continued spread of a virus variant that has already has
been reported in seven MSM in Stockholm [17]. The first patient
in this transmission cluster was infected in 1994 (or earlier) and the
last two in 2010, which shows that this virus variant has been
transmitted in Stockholm over a period of at least 16 years and
that the M41L mutation is very stable. Another cluster contained
five viruses that were predicted to have high-level resistance to
most NRTIs, NNRTIs and PIs. Clustering of TDR viruses have
been reported before and has been interpreted to suggest onward
transmission of TDR viruses [36,37]. It is difficult to estimate how
often onward transmission occurred in our study, but it is likely
that some of the 18 patients in the M41L cluster represent onward
transmission because it is improbable that one patient transmitted
to all others.
As reported in some earlier studies a majority (54 of 82; 68%)
of the patients with TDR had viruses with singleton resistance
mutations [9,13]. Many of these viruses with singleton mutations
and also some viruses with two or more resistance mutations were
predicted to be fully sensitive to all registered NRTIs, NNRTIs
and PIs. Thus, the corresponding patients would be expected to
respond well to standard ART. However, we cannot exclude the
possibility that some patients with or without signs of TDR in
bulk sequences might have resistant viruses represented as
minority HIV-1 variants that might impact negatively on
response to ART [38]. However, TDR may also be over-
estimated because of the presence of natural sequence polymor-
phisms [39]. Some other limitations of the study should be
mentioned. First, the study covered 44%, but not all, patients
diagnosed in Sweden during the study period from January 2003
to June 2010. Second, MSM were somewhat over-represented in
the study population, which may suggest that the true prevalence
of TDR in Sweden may be somewhat lower than our estimate of
5.6%.
In conclusion, this study shows that the prevalence of TDR in
Sweden 2003–2010 was lower than in many other European
countries, but that TDR was concentrated among MSM. In this
group, we also found evidence for clustering of TDR strains, which
highlights the need for continued and improved measures for
targeted interventions.
Low HIV-1 Transmitted Drug Resistance in Sweden
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33484Figure 1. Maximum likelihood phylogenetic analysis of study subjects infected with HIV-1 of subtype B. The upper panel shows the
complete tree, which includes sequences from 605 study subjects, 194 MSM diagnosed as HIV-1 infected in Stockholm 1992–2002 [17], and four
subtype B and four subtype D reference sequences (www.hiv.lanl.gov). The tree was generated using partial HIV-1 pol gene sequences using PhyML
and the best fitted nucleotide substitution model (i.e. GTR+I+G). Twenty-three codons with resistance mutations were removed from the alignment
so that the final alignment contained 987 unambiguously aligned nucleotides. The tree is rooted using the four subtype D reference sequences. Red
branches represent sequences with mutations indicative of TDR according to the WHO 2009 list of mutations for surveillance of transmitted drug
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